You are currently viewing Salignostics, World’s First Saliva-Based Pregnancy Test, Launched in UK & Ireland

Salignostics and Abingdon Health, has just launched the Salistick™, the first saliva-based pregnancy test,  with Superdrug, a leading health and beauty retailer in the United Kingdom and Ireland, initially rolling out into 400 stores and online. Superdrug trades from almost 900 stores across the United Kingdom.

Last year an estimated 12.5 million pregnancy tests were used in the UK – with women having to pee on a stick or collect urine to find out if they were expecting. The US market is estimated at 20 million pregnancy tests and it is expected to double by 1930. The global pregnancy test kits market was valued at USD 1.70 billion in 2022 and is expected to reach USD 2.28 billion by 2028, growing at a CAGR of 5.08%

While home pregnancy tests have been a big success – women didn’t have to go to the doctors for an answer and could get results in private, they have always been messy and awkward, as a woman needs to collect and test her urine. Salignostics, by introducing Salistick™, a saliva-based pregnancy test, eliminates the mess and awkwardness. This could be another major milestone for women’s pregnancy tests.

Abingdon Health chief executive officer Chris Yates stated, “This novel technology provides women with an enhanced user experience; offering the ability to test anywhere, anytime, and for the testing experience to be shared with a partner and other loved ones. We are pleased to have supported our partner Salignostics Ltd  through the development process into manufacturing and now commercial launch, and we look forward to deepening our collaboration as we move forward.”

As well as providing distribution support, Abingdon Health has been providing Salignostics with contract development services in scaling up the Salistick™ product for manufacture and will continue to provide Salignostics with contract manufacturing services going forward.

In addition, Salistick™ will also launch through Abingdon Health‘s direct-to-consumer e-commerce channel Abingdon Simply Test. Salistick™ is co-branded Abingdon Simply Test™, with the Abingdon Simply Test™ range now including over 15 self-tests. Abingdon Health intends to continue expanding the range of innovative self-tests it makes available to consumers through partnering with companies such as Salignostics to offer the very best in novel self-test technology to the market.

Where can you buy the Salistick?

The test, which costs £9.99 and is being sold in 400 high street stores and online. You can purchase it at Superdrug Online: https://www.superdrug.com/health/conception/pregnancy-tests/salistick-the-worlds-first-saliva-pregnancy-test/p/833569?utm_source=facebook&utm_medium=organic_social&utm_campaign=June-facebook-saliva-pregnancytest

Salistick is also available in Israel, UAE, and South Africa.

How do you use the test?

The testing process is relatively simple – saliva is pooled in the mouth before the collection swab is inserted to gather the sample. You have to wait until the indicator on the swab changes color to learn if you have collected enough saliva for the test to work. The swab is then inserted into the test unit where it mixes with the buffer solution and migrates across the lateral flow strip. Results can be read between five to 15 minutes but may show up as early as three minutes.

How reliable is the new test compared to traditional ones?

The Salistick test has a 95 percent accuracy from day two of your missed period. Most at home pregnancy tests claim to have a 98 to 99 percent accuracy when used exactly as instructed.

Guy Krief, CEO, Salignostics said: “Many pregnancy tests quote a 99 percent accuracy on their packaging, but in actuality, the accuracy differs depending on when you take the pregnancy test. For example, two of the ‘ultra early’ pregnancy tests provided by market leaders, indicate a >99 percent accuracy on the packaging but within the fine print, you’ll find that the accuracy six days before the day of a missed period is actually only 71 and 76 percent. Studies indicate that the clinical performance of the Salistick Test Kit is comparable to the clinical results of the traditionally used urine-based home pregnancy test (HPT) kits, thus, this saliva-based device is believed to be an appropriate alternative biomarker, but with a more user-friendly and acceptable biofluid, i.e., saliva, for detection of early pregnancy.”

How does Saliva based diagnostics work?

According to Salignostics, saliva contains over 5,000 identified proteins that mirror and overlap with the physiological state of one’s blood. Drawing from the same principles used to develop SaliCov, its rapid antigen saliva test kit to detect Covid-19, Salistick can detect the pregnancy hormone B-hcG in saliva and delivers proven and accurate detection rates for early pregnancy.

Pregnancy detection kits are medical devices designed to detect the presence of human chorionic gonadotropin (hCG) hormone in a woman‘s urine. This hormone is produced by the placenta shortly after fertilized egg implants in the uterus. Levels of hCG rise rapidly in early pregnancy, and this is what home pregnancy tests are checking for. Salignostics succeeded in detecting the presence of human chorionic gonadotropin (hCG) hormone in a woman’s saliva with results matching the best of the urine-based pregnancy tests. This means that a woman is no longer confined to her bathroom to do a home pregnancy test but can do it anywhere!

Professor Aharon Palmon, Co-Founder of Salignostics, commented on how saliva is vital for quick diagnosis of numerous medical issues: “Saliva is the key to rapid diagnostics for various medical reasons. It is the only non-invasive, easy, and hygienic means to detect hormones, viruses, and even diseases”. He added, “With SaliStick, we leverage the powerful diagnostics abilities we have been able to create from analyzing saliva. This product completely removes the need for blood and urine samples when testing for pregnancy.”

Salignostics has received the European Union’s CE mark for Salistick and has completed a 510(k) initial submission of the test kit to the FDA in the US. The company has successfully completed clinical trials in Israel on more than 300 women, both pregnant and non-pregnant, and has completed thousands of analytical trials.

About Salignostics

Salignostics was founded in 2016 at the Hebrew University Medical Center of Jerusalem in Ein Kerem by a group of five like-minded Ph.D.s who identified a growing need for a cost-effective user-friendly means to monitor health well-being and disease onset through non-invasive means. The founders were Prof Aaron Palmon, (president), Dean of The Hebrew University – Hadassah School of Dental Medicine, Dr Omer Deutsch (co-CEO), Dr Guy Krief (co-CEO and cBDO), Dr Raluca Cohen (CSO) and Dr Yoav Neumann (CFO). The founders all dealt with various aspects of saliva during their doctoral studies. They found that saliva-based diagnostics could match the precision of blood-based diagnostic lab tests.

Salignostics is an Israeli company that has been developing technologies that transform saliva into a reliable body-fluid sample for lateral flow immunoassays like this β-hCG Pregnancy Rapid Test. The ingenuity of this technology lies in the ability to overcome physiological obstacles found in the chemical, biological, and physical features of saliva. Salignostics’ method provides a revolutionary technological platform for saliva diagnostics across a wide range of possible uses.

Pregnancy tests were the most common tests in pharmacies and the Salignostics team set out to develop a saliva-based test to detect pregnancy as accurately but not as awkwardly as the current urine–based pregnancy tests.

Salignostics, which raised $8 million in a Series A round last year, also offers a saliva-based test for SARS-CoV-2, called SaliCov.

For further information, see: Salignostics ( https://www.salignostics.com/)

 

About JLM- BioCity

News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/

JLM-BioCity is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.

We invite you, researcher, professional, investor, and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.

If you want your company featured in our blogs, news releases, please contact: info AT jlm-biocity.org